Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News
Skip to content
overview - Kinnear Pharmaceuticals overview - Kinnear Pharmaceuticals

Kinnear Pharmaceuticals


  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News

Kinnear Pharmaceuticals

overview

Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News

Overview

At Kinnear Pharmaceuticals, we’re pioneering the future of anti-infective and anti-inflammatory therapies. As a dynamic, preclinical stage company, our focus is on developing innovative Ceragenin-based treatments to address diseases that currently lack effective solutions. Our mission is deeply rooted in discovering, developing, and bringing to market revolutionary product candidates.

Kinnear Pharmaceuticals is a subsidiary of N8 Biosciences (www.n8medical.com), a holding company dedicated to the broad application of Ceragenins. N8 Biosciences focus includes the commercialization of CeraShield technology, a specialized coating for medical devices aimed at preventing hospital-acquired infections (HAIs).
The Company’s proprietary technology is based on Dr. Paul B. Savage’s research and invention at Brigham Young University (BYU).

What sets our Ceragenins apart? These synthetic molecules are designed to mimic endogenous host defense peptides – nature’s own way of combating pathogens. They replicate the multifaceted activities of natural antimicrobial peptides, but with enhanced stability and manufacturability. Unlike peptides, Ceragenins are not susceptible to proteolytic degradation and can be produced on a large scale, making them a practical solution for widespread use.

Here's why Ceragenins are groundbreaking:

  • They possess a unique mechanism of action, distinct from traditional treatments.
  • Their antimicrobial potency is exceptional, effectively targeting multidrug-resistant strains and biofilms.
  • They have a reduced likelihood of prompting bacterial resistance – a significant advancement in infectious disease treatment.
  • Beyond fighting infections, Ceragenins have promising anti-inflammatory properties and can synergize with conventional antibiotics.
  • Our innovative approach is secured by patent protection extending into the mid-2030s and beyond.

Kinnear Pharmaceuticals is more than a treatment developer; we're at the vanguard of transforming healthcare for challenging conditions underserved by current medical solutions, particularly those arising from deficiencies in LL-37 or caused by drug-resistant and biofilm-associated infections.

Lets Get in Touch!

  • 1 (702) 285-5740
  • info@kinnearpharma.com
  • Fax: (877) 686-3318
  • 3960 Howard Hughes Parkway, Las Vegas, NV, 89169

Follow now

Linkedin
footerform
Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News
Built with BoldGridPowered By DreamHost
Menu
  • Home
  • Overview
  • Science
  • Pipeline
  • Leadership
  • News

©2019 Kinnear Pharmaceuticals, LLC